APA (7th ed.) Citation

Motzer, R. J., Penkov, K., Haanen, J., Rini, B., Albiges, L., Campbell, M. T., . . . Choueiri, T. K. (2019). Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma. The New England journal of medicine, 380(12), 1103-1115. https://doi.org/10.1056/NEJMoa1816047

Chicago Style (17th ed.) Citation

Motzer, Robert J., et al. "Avelumab Plus Axitinib Versus Sunitinib for Advanced Renal-Cell Carcinoma." The New England Journal of Medicine 380, no. 12 (2019): 1103-1115. https://doi.org/10.1056/NEJMoa1816047.

MLA (9th ed.) Citation

Motzer, Robert J., et al. "Avelumab Plus Axitinib Versus Sunitinib for Advanced Renal-Cell Carcinoma." The New England Journal of Medicine, vol. 380, no. 12, 2019, pp. 1103-1115, https://doi.org/10.1056/NEJMoa1816047.